Applied DNA’s LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
April 21st, 2025
All Categories
ACDL
APDN in the News
CertainT®
Coronavirus
Corporate/Financial News
Investors
Large-Scale DNA Production
Linear DNA
mpox
PGx
Press Release
Uncategorized
Vaccines
Category: Linear DNA
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
January 10th, 2025
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-cell Therapy Produced from LineaDNA
December 18th, 2024
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
September 17th, 2024
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
July 29th, 2024
Applied DNA and Alphazyme Conclude Linea™ RNAP Manufacturing Scale-Up Project, Deliver Substantial Improvement in Linea™ IVT Platform Economics
June 20th, 2024
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea™ IVT Platform
June 5th, 2024
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s Linea DNA™ for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
May 13th, 2024
APDN Awarded Contract by HDT Bio For Rapid Vaccine Development Program
April 25th, 2024